OstomyCure is a medical technology company that has developed a revolutionary technology called Transcutaneous Implant Evacuation Solution (TIES). The TIES Continent Ileostomy Solution is a titanium implant solution with lid intended to replace a conventional ileostomy. It allows the patients to exercise their needs when it suits them and minimises skin complications, in contrast to the conventional stoma that continually empties itself into a bag, causing discomfort, noise and smell. TIES facilitates for a more carefree life for patients who suffer from inflammatory bowel diseases such as Ulcerative colitis, cancers or other related diseases that necessitate removal of the colon (large intestine).

The TIES Solution is the result of several years of research combined with the latest 3D manufacturing technology. OstomyCure is now conducting a clinical trial in the UK, Sweden, Austria, Poland and India with the goal of proving the safety and efficacy of the TIES solution.

OstomyCure’s head office is in Oslo, Norway. In addition, the company has offices at the Karolinska Campus in Solna, the heart of the bustling Stockholm life science scene,

OstomyCure is majority-owned by Kistefos which holds 73.9 % of the share capital.

For more information, please visit www.ostomycure.com

Nishant Fafalia

Investment Director

Lars Petter Utseth

Investment Analyst

Key facts

Sector

Medical Technology

Country

Norway

Ownership

73.9%

Entry

2007

Board of directors

Chairman

Graeme Smith

Member

Nishant Fafalia

Member

Lars Petter Utseth

Member

Georg Stang

Member

Lars Magnus Mikkelsen

Member

Johan Gjesdal

Member

Martin Krekling

Management

CEO

Johan Järte

CFO

Stig Jarle Pettersen